Cathay Fortune, a Shanghai PE firm, will pay $186 million to acquire Berlin’s Epigenomics and its blood plasma colorectal cancer test; Singapore’s Aslan Pharma will conduct a Taiwan IPO in May and begin trading in June; EpimAb of Shanghai closed a $25 …
( read original story …)